Flonoltinib maleate is under clinical development by Chengdu Zenitar Biomedical Technology and currently in Phase II for Coronavirus Disease 2019 (COVID-19).

Anti-CDH17 CAR-T Cells is under clinical development by UTC Therapeutics and currently in Phase I for Pancreatic Cancer.

Anti-CDH17 CAR-T Cells is under clinical development by UTC Therapeutics and currently in Phase I for Colorectal Cancer.

Biopharma and currently in Phase I for Metastatic Pancreatic Cancer. According to GlobalData, Phase I drugs for Metastatic Pancreatic Cancer have an 88% phase transition success rate (PTSR) indication ...

Alphaf-001 is under clinical development by Alpha Fusion and currently in Phase I for Follicular Thyroid Cancer.

AGA-2118 is under clinical development by Angitia Biopharmaceuticals and currently in Phase II for Post Menopausal Osteoporosis.

Fosigotifator is under clinical development by Calico Life Sciences and currently in Phase II for Unspecified Central Nervous System Disorders.

SHRA-1921 is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Metastatic Breast Cancer.

ABX-002 is under clinical development by Autobahn Therapeutics and currently in Phase II for Major Depressive Disorder.

Zurletrectinib is under clinical development by InnoCare Pharma and currently in Phase I for Central Nervous System (CNS) Tumor.

BAT-8006 is under clinical development by Bio-Thera Solutions and currently in Phase II for Epithelial Ovarian Cancer.

Macupatide (LY-3532226) is under development for the treatment of type 2 diabetes, obesity and type 1 diabetes mellitus. It is administered through subcutaneous route. It is a long acting new ...